Haidl Friederike, Pfister David, Heidenreich Axel, Heidegger Isabel
Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Kerpener Straße 62, 50937 Cologne, Germany.
Department of Urology, Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.
Memo. 2017;10(4):202-205. doi: 10.1007/s12254-017-0375-8. Epub 2017 Dec 4.
The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a literature search was conducted using Medline; moreover we performed a systematic review of data presented at this year's important urooncological meetings. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; however, larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice.
在癌症治疗中使用抗血管生成药物已成为肿瘤学研究中一个有吸引力的目标。然而，在泌尿肿瘤领域，目前的指南仅推荐在转移性肾细胞癌中使用抗血管生成药物。然而近年来，除肾细胞癌外，其他泌尿生殖系统恶性肿瘤中使用血管生成抑制剂进行序贯治疗的几种方法正在进行中。因此，本综述文章旨在概述抗血管生成药物在前列腺癌、膀胱癌、睾丸癌以及阴茎癌患者中的临床研究。为此，使用Medline进行了文献检索；此外，我们对今年重要的泌尿肿瘤学会议上展示的数据进行了系统综述。初步数据显示，前列腺癌、膀胱癌、睾丸癌以及阴茎癌中有几项有前景的研究正在进行；然而，应该进行更大规模的研究以优化抗血管生成药物在临床实践中的使用。
